Saniona Initiates Phase 1 Clinical Trial of SAN711
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patientin a Phase 1 clinical trial of SAN711,a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine.SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 receptors and may be applicable in the treatment of rare neuropathic disorders. Data from the trial are expected in the first half of 2022.
The Phase 1 clinical trial will be conducted in approximately 80 healthy volunteers. The primary objective of the study is to determine the tolerability and the maximum tolerated dose of SAN711, which will be evaluated through single ascending dose and multiple ascending dose phases of the study. The secondary objective is to measure binding to target receptors, which will be assessed during a positron emission tomography (PET) evaluation phase of the study. The clinical trial is being conducted in the United Kingdom (U.K.) under the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA). After completion of the Phase 1 clinical trial, Saniona intends to select a lead indication and file an Investigational New Drug (IND) application with the United States Food & Drug Administration (U.S. FDA) to support Phase 2 studies for SAN711 in the U.S.
“SAN711 has demonstrated efficacy in multiple preclinical models of neuropathic pain, and we look forward to assessing its potential in clinical trials,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “Importantly, SAN711 is the first product candidate from Saniona’s proprietary ion channel drug discovery engine that our team has internally advanced into clinical trials. We believe it will be the first of many, as we have multiple additional ion channel modulators in research and preclinical development.”
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: firstname.lastname@example.org
The information was submitted for publication, through the agency of the contact person set out above, at 12.45 CEST on 30June2021.
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 receptors that may be applicable in the treatment of rare neuropathic disorders. SAN711 emerged from Saniona’s proprietary ion channel drug discovery engine and was designed to selectively enhance the effects of GABA-A on α3 containing receptors. Preclinical studies have indicated that this selectivity may allow SAN711 to provide pain relief and other benefits in the central nervous system while avoiding the typical adverse effects associated with non-selective GABA-A activation such as sedation, motor instability, cognitive impairment, abuse liability and physical dependence. Saniona is currently evaluating SAN711 in a Phase 1 clinical trial.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
FLSmidth to acquire thyssenkrupp’s Mining business – creating a global industry leader in mining technology29.7.2021 12:39:04 CEST | Press release
Company Announcement No. 7 2021 FLSmidth and thyssenkrupp Industrial Solutions AG (a fully owned subsidiary of thyssenkrupp AG, "thyssenkrupp") have reached an agreement that FLSmidth will acquire thyssenkrupp’s Mining business1 (TK Mining) for a total consideration (enterprise value) of EUR 325 million, corresponding to approximately DKK 2.4 billion. Closing of the transaction is expected in H2 2022 and is subject to customary approvals from relevant authorities. TK Mining is a leading full-line supplier of solutions for mining systems, material handling, mineral processing and services, which is highly complementary to FLSmidth’s offering. TK Mining has an asset light business model and is present in 24 countries with engineering and global service centres, and has close to 3,400 employees. In 20202, revenue was EUR 780 million (approximately DKK 5.8 billion) with around one-third deriving from services. The business delivered a high single-digit negative EBIT margin and is expected
Millicom to repurchase own shares29.7.2021 12:02:00 CEST | Press release
Millicom to repurchase own shares Luxembourg, July 29, 2021 – On May 4, 2021, the Annual General Meeting of Shareholders (“AGM”) of Millicom resolved to authorize (the “Authorization”) the Board of Directors of Millicom (the “Board”) to adopt a share repurchase plan. Based on the Authorization, the Board has decided to initiate a repurchase program comprising not more than 5,000,000 Swedish Depository Receipts representing the Company’s ordinary shares (“SDRs”). The purposes of the share repurchase plan may include: reduction of Millicom's share capital; meeting obligations for Board remuneration; and/or meeting obligations under Millicom’s share-based incentive plans or other compensation programs. The repurchase program will be implemented in accordance with the Authorization, the Nasdaq Nordic Main Market Rulebook for Issuers of Shares (“Nasdaq Rulebook”), and applicable law including the Luxembourg law of 10 August 1915 on commercial companies, as amended, and the EU Market Abuse R
Fobi Wallet Pass For Ticketing And Global Fan Engagement Powers bdG Sports “Baha Mar Hoops” Tournament Featuring 19 NCAA Men’s And Women’s Basketball Teams, Including US Thanksgiving Nationally Televised Events29.7.2021 12:00:00 CEST | Press release
After multiple event successes with bdG Sports, Fobi is now adding ticketing and admissions capabilities to live and digital fan engagement to deliver a comprehensive solution for the “largest early season event in all of college basketball” at Baha Mar Hoops in The Bahamas VANCOUVER, British Columbia., July 29, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (formerly Loop Insights Inc.) (TSXV: FOBI) (OTCQB: FOBIF) (the "Company" or "Fobi"), is pleased to announce it will once again be supporting bdG Sports for college basketball’s largest early season event. The invite-only global event at Baha Mar Convention Center in Nassau, The Bahamas will take place from November 22-27, 2021 and will use Fobi’s Wallet Pass platform for ticketing, admission, and fan engagement both live and at home. Fobi will earn significant revenue from this event through the event license, ticket fees and fan activations both live and at home, including nationally televised and digital audiences across the United States
Building momentum and delivering results29.7.2021 12:00:00 CEST | Press release
Building momentum and delivering results Luxembourg, July29, 2021– Millicom is pleased to announce its second quarter 2021 results. Please find below links to the Q2 2021 Earnings Release and H1 2021 Interim Condensed Consolidated Financial Statements. Millicom Chief Executive Officer Mauricio Ramos commented: "We had an outstanding Q2. We built on our robust Q1 performance and delivered double-digit growth in both service revenue and EBITDA. In Colombia, we now have the best mobile network, and we capitalized on this in Q2 by leading the market in portability and by adding a record number of new postpaid customers. Our rapid customer and revenue growth is a direct result of our unwavering commitment to delivering the best customer experience, including network quality and reliability. With that in mind, and considering our healthy cash flow generation, we have accelerated investments that we expect will help us drive faster growth in all our businesses going forward. In light of our s
Summary of AB Klaipedos nafta webinar29.7.2021 11:30:00 CEST | Press release
On the 29th July 2021, AB Klaipedos nafta (KN) held an investor conference webinar where KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė commented Company’s financial results for the six months of 2021. Webinar recording is available online at: https://youtu.be/BmHfUpOVmEM The presentation demonstrated during the webinar is attached to this announcement. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2
Correction: AB Klaipėdos nafta financial information reporting dates in 202129.7.2021 10:15:00 CEST | Press release
Correction: AB Klaipedos nafta interim financial information for the 6 months of 2021 has been released on 29 July 2021. AB Klaipėdos nafta (further – KN) informs that it plans to release financial information in 2021 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2021KN preliminary revenues for the previous month29 January 2021Interim financial information for the year 20207 April 2021Audited financial statements for the year 202030 April 2021Interim financial information for the 1st quarter of 20218 June 2021Social responsibility report for the year 202029 July 2021Interim financial information for the 6 months of 202129 October 2021Interim financial information for the 3 quarters of 2021 On 30 April 2021, the Company plans to convene an Ordinary General Meeting of Shareholders. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276.
Hexagon Digital Wave signs new equipment and service agreement with Linde29.7.2021 09:00:00 CEST | Press release
Hexagon Digital Wave, a business of Hexagon Composites has signed an agreement with Linde, a leading industrial gas and engineering company. The agreement covers the supply and service of Ultrasonic Examination (UE) testing equipment. The estimated total value of the agreement is USD 2 million (approx. NOK 17 million) and designates Hexagon Digital Wave as a long-term partner. Driving energy transformation “We are excited to extend our relationship with the great team at Linde”, says Keith Fountain, UE international Sales Manager Hexagon Digital Wave. “Over the past 14 years we have provided our equipment to one of the market leaders in the industrial gas environment and helped to improve the safety of their cylinders.” About the market The non-destructive UE test and process enables the recertification of the cylinders without removing the internal product which improves the safety and allows a number of ESG requirements to be accomplished. Positive environmental impacts are accomplis